MedTrace Logo

Study of TNF-Antagonism in the Metabolic Syndrome (II)

NCT00413400 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-12-02

Study results available
· View outcomes & findings →

Summary

This study will investigate whether etanercept will result in improved inflammatory indices, glucose tolerance and endothelial function in patients with the metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Etanercept

50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months

DRUG

Placebo

50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Steven K Grinspoon · MGH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413400 on ClinicalTrials.gov